Investors are a little more bearish on shares of the company lately if you take into consideration the rise in short interest. The firm saw a rise in short interest of 8.09% between September 29, 2017 and October 13, 2017. Short shares grew 72,301 over that period. With short interest at 966,304 and short average daily volume at 107,962, the short-interest ratio is 9.0 and the short interest percentage is 0.08% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of quarter end Caprock Group, Inc. had sold a total of 195 shares trimming its holdings by 4.3%. The value of the investment in ANI Pharmaceuticals, Inc. went from $213,000 to $229,000 a change of $16,000 quarter to quarter. As of the end of the quarter First Manhattan Co had disposed of 2,800 shares trimming its position 0.7%. The value in dollars increased from $17,615,000 to $19,610,000 increasing 11.3% since the last quarter.
As of quarter end Nationwide Fund Advisors had sold 11,382 shares trimming its stake by 68.3%. The value of the total investment in ANI Pharmaceuticals, Inc. decreased from $780,000 to $278,000 a change of 64.4% for the reporting period. Raymond James Financial Services Advisors, Inc. augmented its investment by buying 530 shares an increase of 5.6% in the quarter. Raymond James Financial Services Advisors, Inc. currently owns 10,023 shares worth $526,000. The value of the position overall is up by 18.5%.
On July 31 analysts at Canaccord Genuity released its first research report on the stock setting a rating of “Buy”. October 16 investment analysts at Canaccord Genuity held the stock rating at “Buy” and raised the price expectation to $66.00 from $60.00.
The company is so far trading down since yesterday’s close of $58.08. Shares last traded at $58.08 just above $54.35, the 50 day moving average and well above the 200 day moving average of $49.21. The 50 day moving average went up $3.74 or +6.87% and the 200 day average went up $8.87 or +18.03%.
The P/E ratio is currently 127.09 and market cap is 675.94M. In the last earnings report the EPS was $0.46 and is expected to be $3.84 for the current year with 11,638,000 shares outstanding. Next quarter’s EPS is expected be $1.12 with next year’s EPS anticipated to be $4.56.
ANI Pharmaceuticals, Inc., launched on April 11, 2001, is an integrated specialty pharmaceutical company. The Company is involved in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota..